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Abstract
Background: The assessment of treatment success in clinical trials when multiple (repeated) doses (courses) are
involved is quite common, for example, in the case of infertility treatment with assisted reproductive technology
(ART), and medical abortion using misoprostol alone or in combination with mifepristone. Under these or similar
circumstances, most researchers assess success using binomial proportions after a certain number of consecutive
doses, and some have used survival analysis. In this paper we discuss the main problems in using binomial proportions
to summarize (the overall) efficacy after two or more consecutive doses of the relevant treatment, particularly for the
case of misoprostol in medical abortion studies. We later discuss why the survival analysis is best suited under these
circumstances, and illustrate this by using simulated data.
Methods: The formulas required for the binomial proportion and survival analysis (without and with competing risks)
approaches are summarized and analytically compared. Additionally, numerical results are computed and compared
between the two approaches, for several theoretical scenarios.
Results: The main conceptual limitations of the binomial proportion approach are identified and discussed, caused
mainly by the presence of censoring and competing risks, and it is demonstrated how survival analysis can solve these
problems. In general, the binomial proportion approach tends to underestimate the “real” success rate, and tends to
overestimate the corresponding standard error.
Conclusions: Depending on the rates of censored observations or competing events between repeated doses of
the treatment, the bias of the binomial proportion approach as compared to the survival analysis approaches
varies; however, the use of the binomial approach is unjustified as the survival analysis options are well known
and available in multiple statistical packages. Our conclusions also apply to other situations where success is
estimated after multiple (repeated) doses (courses) of the treatment.
Keywords: Medical abortion, Binomial proportion, Survival analysis, Competing risks
Background
The World Health Organization (WHO) indicates that for
pregnancies of gestational age between 9 and 12 weeks
(63–84 days), the recommended method for medical abor-
tion is 200 mg mifepristone administered orally followed
36 to 48 hours later by 800 μg misoprostol administered
vaginally. Subsequent misoprostol doses should be 400 μg,
administered either vaginally or sublingually, every 3 hours
up to a maximum of four further doses. For pregnancies
of gestational age over 12 weeks (84 days), the recom-
mended method for medical abortion is 200 mg mifepris-
tone administered orally followed 36 to 48 hours later by
an initial dose of 400 μg orally or 800 μg vaginally, with
further doses of 400 μg misoprostol administered either
vaginally or sublingually every three hours, up to four fur-
ther doses [1].
Under these or similar circumstances, many papers as-
sess the efficacy of multiple doses of misoprostol calcu-
lating the binomial proportion of successful abortions
(without surgical intervention) after a certain number of
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consecutive doses (or courses), usually two [2–8]; see
also studies included in the systematic review [9]. Other
studies also use formal survival analysis of “induction to
conception expulsion” time, in hours [10, 11].
To the best of our knowledge, no paper has attempted
to discuss or question the statistical approaches to be
applied under these circumstances, the exception being
Gallo and co-authors [9]. These authors did not address
the topic in detail (just one paragraph within the “out-
come measures” section) but make two main points; first
they argue that the efficacy of a second dose of miso-
prostol should not be estimated from those who fail with
the first dose and go for the second dose, because of the
(obvious) attrition bias [12] that would render inappro-
priate any comparisons between success rates of the sec-
ond versus the first dose. Though this is correct, we
have not seen any studies comparing the efficacy across
doses (such as second versus first or third versus first).
Secondly, the authors argue that the use of binomial
proportions to summarize the success of several con-
secutive doses of misoprostol (the combined or overall
success rate) ignores important information that is
accounted for when survival analysis techniques are ap-
plied. This is undoubtedly the case, but we need to spe-
cify the additional information that is provided, how to
use it, and the eventual impact on the final results.
In this paper we present the main problems encoun-
tered when using binomial proportions to summarize
(the overall) efficacy after administration of two or more
consecutive doses of misoprostol in medical abortion
studies. We later discuss why the competing risk survival
analysis is best suited under these circumstances, and il-
lustrate this by using simulated data. Finally we present
some concluding remarks. In this paper “successful
abortion” stands for “complete expulsion of the products
of conception without surgical intervention”.
Methods
We present and compare four statistical approaches for
assessing success when using multiple doses, the bino-
mial proportion approach and three survival analysis ap-
proaches: Kaplan-Meier, Life Table, and the (Competing
Risk) Cumulative Incidence rate.
At first the approaches are analytically compared in
terms of biases in point estimations and corresponding
standard errors. Additionally, 18 artificially created sce-
narios are generated combining three levels for the rate
of the main event with the first dose, two levels for the
rate of the main event with the second dose, and three
levels for the rate of the competing risk event and cen-
soring, and the approaches are then numerically com-
pared in Table 1.
The three levels assumed for the rate of the main
event with the first dose were “low 70 %”, “medium
80 %”, and “high 90 %”; the two levels assumed for the
rates of the main event with the second dose were “low”
and “high” corresponding to 12 % and 6 % relative re-
duction with respect to the first dose’s rate. The three
levels assumed for the rates of the competing event and
censoring with the first dose were “low”, “medium”, and
“high” corresponding to 5 %, 10 %, and 20 % of all
remaining units (columns {3} and {4} in Table 1). For the
second dose we assumed an almost zero rate (1 %) of
censoring and all other remaining subjects were recon-
verted into the competing risk event (surgical abortion),
which is the usual practice in these types of studies (see
columns {7} and {8} in Table 1).
The figures in columns {2} to {8} in Table 1 are derived
from the assumed rates in the 18 different scenarios
(rows), and by making the initial sample size equal to
1,000 (=n1, column {1} in Table 1) in all scenarios. Figures
in columns {9} to {13} provide the point estimations for
the four statistical approaches, and figures in columns
{14} to {18} provide the corresponding standard errors,
using the formulas presented in the Results sections. For
the competing risk approach results are presented both
for the rate of the main event and the rate of the compet-
ing event, point estimations (columns {12} and {13}), and
corresponding standard errors (columns {17} and {18}).
Results
The problem of using binomial proportions
A binomial proportion is derived from a random vari-
able X that summarizes the result of “n” independent
repetitions of a Bernoulli experiment, each with prob-
ability “P” of success, by providing the total number of
successes (or the proportion of successes) out of “n” rep-
etitions; the binomial distribution is characterized by
two parameters, “n” and “P” and is denoted as B(n,P).
The probability that X takes the value (number of suc-
cesses) “r” is given by [13]:
P X¼rð Þ¼ n
r
 
Pr 1‐Pð Þn‐r:
The rationale for using a single binomial proportion to
assess the overall efficacy after administration of con-
secutive doses of misoprostol is that, although the prob-
ability of success varies from one dose to the other, we
could say that the entire combined process was con-
ducted with a success probability P = P(Success after 2
doses) that could be estimated by
p ¼ r1 þ r2
n1
ð1Þ
where r1 and r2 are the number of successes after the
first and the second dose, respectively, and n1 is the
number of subjects receiving the first dose; not in the
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Table 1 Estimation of the success rate of medical abortion after two doses of misoprostol under different scenarios for the rates of the main event medical abortion, the
competing event surgical abortion, and censored data ({1}–{8}), using the binomial approach ({9}, {14}), the Kaplan-Meier (KM) approach ({10}, {15}), the Life Table (LT) approach
({11}, {16}), and the competing risk survival approach ({12}, {13}, {17}, {18})
Rate of main
event with
1st dose
Rate of main
event with
2nd dose (a)
Rate of competing
event and censoring (b)
Assumptions for number of main events (medical
abortions (r1, r2), competing events (d1, d2), and
censored observations (c1, c2)).
POINT ESTIMATION STANDARD ERROR
{1} {2} {3} {4} {5} {6} {7} {8} {9} {10} {11} {12} {13} {14} {15} {16} {17} {18}
n1 r1 d1 c1 n2 r2 d2 c2 bin KMc LTc CI1(2) CI2(2) bin KMc LTc CI1(2) CI2(2)
Low (70 %) Low (62 %) Low 1000 700 15 14 271 168 102 1 86.79 % 88.60 % 93.20 % 87.67 % 12.23 % 1.07 % 1.04 % 0.90 % 1.03 % 1.03 %
Medium 1000 700 30 27 243 151 91 1 85.07 % 88.64 % 93.47 % 86.78 % 13.11 % 1.13 % 1.08 % 0.91 % 1.06 % 1.06 %
High 1000 700 60 48 192 119 72 1 81.90 % 88.59 % 93.90 % 84.87 % 15.00 % 1.22 % 1.19 % 0.95 % 1.11 % 1.11 %
High (66 %) Low 1000 700 15 14 271 179 91 1 87.89 % 89.82 % 94.08 % 88.82 % 11.07 % 1.03 % 0.99 % 0.83 % 0.99 % 0.99 %
Medium 1000 700 30 27 243 160 82 1 86.04 % 89.75 % 94.24 % 87.78 % 12.11 % 1.10 % 1.04 % 0.85 % 1.02 % 1.02 %
High 1000 700 60 48 192 127 65 0 82.67 % 89.84 % 94.70 % 85.87 % 14.12 % 1.20 % 1.14 % 0.88 % 1.08 % 1.08 %
Medium (80 %) Low (70 %) Low 1000 800 10 10 180 126 53 1 92.60 % 94.00 % 96.61 % 93.30 % 6.59 % 0.83 % 0.78 % 0.63 % 0.78 % 0.78 %
Medium 1000 800 20 18 162 113 48 1 91.34 % 93.95 % 96.71 % 92.56 % 7.33 % 0.89 % 0.82 % 0.64 % 0.82 % 0.81 %
High 1000 800 40 32 128 90 38 0 88.96 % 94.06 % 97.03 % 91.25 % 8.75 % 0.99 % 0.89 % 0.65 % 0.87 % 0.87 %
High (75 %) Low 1000 800 10 10 180 135 45 0 93.50 % 95.00 % 97.26 % 94.25 % 5.75 % 0.78 % 0.72 % 0.56 % 0.73 % 0.73 %
Medium 1000 800 20 18 162 122 40 0 92.15 % 95.03 % 97.39 % 93.45 % 6.55 % 0.85 % 0.75 % 0.57 % 0.77 % 0.77 %
High 1000 800 40 32 128 96 32 0 89.60 % 95.00 % 97.57 % 92.00 % 8.00 % 0.97 % 0.83 % 0.59 % 0.83 % 0.83 %
High (90 %) Low (79 %) Low 1000 900 5 5 90 71 19 0 97.13 % 97.89 % 98.87 % 97.49 % 2.51 % 0.53 % 0.47 % 0.36 % 0.49 % 0.49 %
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Table 1 Estimation of the success rate of medical abortion after two doses of misoprostol under different scenarios for the rates of the main event medical abortion, the
competing event surgical abortion, and censored data ({1}–{8}), using the binomial approach ({9}, {14}), the Kaplan-Meier (KM) approach ({10}, {15}), the Life Table (LT) approach
({11}, {16}), and the competing risk survival approach ({12}, {13}, {17}, {18}) (Continued)
Medium 1000 900 10 9 81 64 17 0 96.40 % 97.90 % 98.93 % 97.11 % 2.89 % 0.59 % 0.49 % 0.36 % 0.52 % 0.52 %
High 1000 900 20 16 64 51 13 0 95.06 % 97.97 % 99.06 % 96.37 % 3.62 % 0.69 % 0.54 % 0.36 % 0.57 % 0.57 %
High (85 %) Low 1000 900 5 5 90 77 13 0 97.65 % 98.56 % 99.26 % 98.13 % 1.87 % 0.48 % 0.40 % 0.29 % 0.42 % 0.42 %
Medium 1000 900 10 9 81 69 12 0 96.89 % 98.52 % 99.27 % 97.67 % 2.33 % 0.55 % 0.42 % 0.30 % 0.47 % 0.47 %
High 1000 900 20 16 64 54 10 0 95.44 % 98.44 % 99.29 % 96.75 % 3.25 % 0.66 % 0.48 % 0.31 % 0.54 % 0.54 %
{1} n1: subjects receiving the 1st dose
{2} r1: number of successes after the 1st dose (and before the 2nd)
{3} d1: number of competing events after 1st dose (and before 2nd)
{4} c1: number of censored data between the 1st and the 2nd doses
{5} n2: subjects receiving the 2nd dose
{6} r2: number of successes after the 2nd dose (and before end of study)
{7} d2: number of competing events after 2nd dose (and before end of study)
{8} c2: number of censored data between the 2nd dose and end of study
{9}: success rate using the binomial proportion
{10}: success rate using KMc
{11}: success rate using Life Table with actuarial assumptionsc
{12}: success rate using competing risk approach (cmprsk package in R)
{13}: as in {17} but for the competing event “surgical abortion”
{14}: standard error of point estimation in {13}
{15}: standard error of point estimation in {14}
{16}: standard error of point estimation in {16}
{17}: standard error of point estimation in {17}
{18}: standard error of point estimation in {18}
a: rate of event with second dose was assumed lower than with first dose, “low” (12 % relative reduction) and “high” (6 % relative reduction)
b: For j = 1, as a fraction of (n1-r1), or (n1-r1-d1): low = 5 %, medium = 10 %, high = 20 %; for the second dose, c2 = 0.01*(n2-r2), and d2 = n2-r2-c2
c: All events occur exactly at times (doses) 1 and 2. Life Table and KM rates were computed with SPSS, and Cumulative Incidence (CI) rates with cmprsk package in R; for this purpose 18 datasets were created
replicating the assumptions in columns {1} to {8}, and the corresponding packages were applied
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formula but we also have n2 as the number of subjects
receiving the second dose. When we compute the pro-
portion of success after two doses we are assuming that
there is a unique compact follow-up period during
which we observe the occurrence of the event, from ad-
ministering the first dose up to some predetermined
time after administering the second, for example,
24 hours; the probability of the event might vary sub-
stantially during this period, but we are not interested in
(or prefer to ignore) this feature [14].
Under certain circumstances ignoring this heterogen-
eity might not be advisable. For example, in epidemi-
ology, if a (potential risk) factor increases the odds of a
disease in men, and decreases it in women, saying that
the factor does not impact the disease in the entire
population might not be very useful; similarly in meta-
analysis, merging individual studies with significant vari-
ability could be misleading.
As an alternative to (1), it might seem preferable to
consider the following:
P Success after 2 dosesð Þ
¼Pð Success after 1st doseð Þ or ðSuccess after 2nd dosejFailure after 1st doseÞÞ
¼P Success after 1st doseð Þ
þPðSuccess after 2nd dosejFailure after 1st doseÞ ≙ r1
n1
þ r2
n2
ð2Þ
as the two events are exclusive, “(Success after 1st dose)”
and “(Success after 2nd dose|Failure after 1st dose)”.
However (2) is wrong because the events come from dif-
ferent experiments.
Therefore, we have to approach our problem not as
the sum of two exclusive events but as the (complement
of the) product of two dependent events, as is done in
survival analysis with the complement of the survival
probability, or failure function [15, 16], that is:
P Success after 2 dosesð Þ¼1‐P No abortion during the 2 first dosesð Þ
¼1‐fP No abortion after 1st doseð Þ
 PðNo abortion after 2nd dosejNo abortion after 1st doseÞg
≙1‐ 1‐
r1
n1
0
@
1
A 1‐ r2
n2
0
@
1
A :
ð3Þ
Assuming the study ends at a specific time after the
last (second) dose and that there are no “censored obser-
vations” (see the next section), it can be easily proved
that (1) = (3), using n2 = n1 − r1.
The standard errors for (1) and (3) are given by
SE pð Þ≙
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
p 1‐pð Þ
n1
s
ð4Þ
and
SE pð Þ≙
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1−pð Þ2 r1
n1 n1−r1ð Þþ
r2
n2 n2−r2ð Þ
 s
ð5Þ
respectively [15], which again can be easily proved are
the same under the assumption of no censored data
(n2 = n1 − r1).
Therefore, assuming there is no censored data and
ignoring the heterogeneity issue mentioned above,
using the binomial proportion (1) poses no problem.
However, the assumption of no censored data is not
realistic because in longitudinal studies censored data
are usually present; in these cases n2 = n1 − r1 − c1,
where c1 is the number of censored cases after the
first dose and just before the second, and some c2
subjects might also be censored after administering
the second dose and not available for outcome assess-
ment at the end of the study (at a specific time after
the second dose is administered).
Additionally, the problem with (3) is that in the pres-
ence of censored data n1 and n2 do not properly repre-
sent the number of subjects at risk (of medical abortion)
during the two concerned periods, after the first dose
(and before the second) and after the second dose (and
before the end of study) respectively. We will address
this in more detail in the next section.
The most common reasons for censored cases in med-
ical abortion studies are i) surgical intervention, and ii)
discontinuation or loss to follow-up. (Discontinuation
because of ) “End of study” is in general also a potential
reason for censoring, but in these medical abortion stud-
ies “end of study” cases are usually converted into “surgi-
cal abortion” cases by design, for obvious ethical reasons
[3–7, 10] and [8].
In the presence of censored cases the binomial propor-
tion from (1) and its standard error (4) will, in general,
underestimate the survival rate from (3) and will over-
estimate its standard error (5), respectively, and the lar-
ger the proportion of censored cases (c1/n1or c2/n2) the
larger these biases.
In the next section we discuss the rationale for using a
survival analysis approach and how the estimation from
(3) is usually modified to account for censored data, and
we will explore what drives differences between different
estimations.
The survival analysis approach
In their systematic review of more than one dose of miso-
prostol in medical abortion studies, Gallo et al. state that
survival analysis uses more information than a binomial
proportion, but they do not discuss how this additional
information can or should be incorporated, and the even-
tual impact on the final results [9].
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In a medical abortion study with multiple doses of mi-
soprostol we usually know not only how many doses
each patient may need to reach a successful abortion,
but also the time (for example, hours) from treatment
initiation (oral administration of mifepristone) to observ-
ing the event (expulsion of the product of conception).
Therefore, we can design the survival analysis both in
terms of “number of doses” or in terms of “number of
hours” from treatment initiation to the event. In both
cases we are using more information because the bino-
mial proportion considers the two (or more) consecutive
doses as a unique compact period (with all subjects ex-
posed to the risk of the event throughout). A survival
analysis in terms of number of hours might be difficult
to interpret if we do not precisely link the results to the
timing when doses were administered; on the other
hand, a survival analysis in terms of number of hours
makes sense under the assumption of a predetermined
protocol for the timing of the successive doses.
The most relevant advantage of the survival analysis
approach is that it accounts for censored data, particu-
larly right censored data, that is, when observation ends
before the event is known [15, 17], which is additional
and very important information that is not used (or is
misused) by the binomial proportion. In survival studies
the main variable is time (or some variation) needed for
a unit/subject to develop a particular characteristic or
event, assuming that observation began at a properly de-
fined time t0 for each unit. In this context the survival
time for a unit might not be observed completely for dif-
ferent reasons (for example, loss to follow-up, end of
study), and all we know is that when the subject was last
seen in the study the event had not yet occurred; in
these cases we say that for this subject the observation
(the survival time) was right censored.
Almost always survival methods used in medical abor-
tion studies define time as number of hours, and apply
Kaplan-Meier (KM) as the estimation method ([9–11]).
This method formally updates the estimation of the cu-
mulative incidence probability each time an event (med-
ical abortion) is observed, which in theory might occur
at any time but when exactly the doses are administered.
The Life Table (LT) estimation method wastes infor-
mation in comparison to the KM (LT is based on inter-
val censored data), but it might be more appropriate
when time intervals are defined a priori in terms of the
timing of the successive doses or in terms of the number
of doses administered, because it updates the estimation
when we need it. One of the interesting features of the
LT method is that assumptions about censored data can
be made more flexibly and explicitly; the average num-
ber of patients at risk of the event during the interval
[tj, tj + 1[⋅, ⋅ = 1, 2, and tj the time when the jth dose is ad-
ministered, is defined as
n
0
j¼nj−
1
2
cj ð6Þ
under the assumption that censoring is non-
informative (see the following subsection) and occurs
uniformly during the interval (see [18] and Section 17.2
in [13]); it can easily be seen that the average number of
patients at risk during the interval from (6) can be gen-
eralized to
n
0
j¼nj−kjmjcj ð7Þ
where kj is the relative risk of the event (medical abor-
tion) in the censored versus all those alive at the begin-
ning of the interval, and mj is the fraction of the time
interval that (on average) censored cases were not ex-
posed to the risk of the event. The corresponding esti-
mation of the cumulative incidence probability of
success is then
P Success after 2 dosesð Þ≙1− 1− r1
n01
 
 1− r2
n02
 
ð8Þ
for nj
′ from (6) (or (7)), with (8) now properly account-
ing for censored cases; the corresponding standard error
is obtained from (5) just replacing nj by nj
′,
SE pð Þ≙
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1−pð Þ2 r1
n01 n
0
1−r1ð Þ
þ r2
n02 n
0
2 −r2ð Þ
 s
: ð9Þ
Observe that in the case of just one dose of miso-
prostol (max j = 1), and under the assumption of no
censored data, (8) and (9) become exactly the point
estimate and the corresponding standard error of the
binomial proportion, (1) and (4), respectively. Also
note that both the KM and the LT methods consider
the competing events (see definition in the following
subsection) of surgical abortions as censored data and
are therefore included in cj, j = 1,2.
Accounting for competing risks
In any longitudinal study censored data are observations
that are interrupted for some reason(s); the events gen-
erating these interruptions may or may not influence the
probability of occurrence of the event of interest. If cen-
soring (of our main event observation) is caused by an
alternative event that modifies the probability of observ-
ing the main event, the censoring is called “informative”;
otherwise, the censoring is called “non-informative” (for
example, as was assumed for [6] above).
A competing risk is defined as any event that pre-
cludes (or modifies the probability of ) the onset of the
event of interest [16, 19]; therefore, a competing risk is
an event that generates a particular type of censored
data, or “informative” censored data. For example, surgical
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abortion is a “competing risk” for our main event
medical abortion because the occurrence of the first
prevents (definitely modifies!) the occurrence of the
second; alternatively we can say that we have two dif-
ferent and competing (mutually exclusive) ways of in-
duced abortion, “medical” and “surgical”.
It is evident that a “competing risk” can have different
levels according to the degree to which it influences the
probability of the occurrence of our main event. We can
also have, of course, more than two competing risks,
and potentially they can all compete with each other at
different levels.
The classical KM and LT estimations do not account
for competing risks because they always assume non-
informative censoring; their results can be interpreted as
the survival probabilities under the assumption that
competing risks are non-existent (or have been elimi-
nated), because considering competing risks as non-
informative censoring is, in practice, the closest we can
get to ignoring them. This might be a reasonable ap-
proach if we want to assess (extrapolate) the perform-
ance of medical abortion in a (to a counter-factual)
context where surgical abortion is non-existent; however,
in a context where both medical and surgical abortion
are and will be available, the results from the classical
KM and LT methods are not appropriate because the
survival rate is underestimated (or the cumulative inci-
dence probability is overestimated).
If there are no competing risks (that is, surgical abor-
tion does not exist), we can express the distribution
function (or cumulative incidence probability) of medical
abortion (8) above as
P Success after 2 dosesð Þ≙
X2
j¼1
S tj‐1
  rj
n0j
¼S t0ð Þ r1
n01
þS t1ð Þ r2
n02
ð10Þ
where S(tj) is the probability of survival up to tj and
S(t0) = 1; for example, S(t1) * r2/n2
′ is the probability of
having a medical abortion after the second dose (and be-
fore the planned end of study) given that the patient did
not have a medical abortion after the first dose (and be-
fore the second).
When k(k = 1 to K) competing risks are present, [10]
can be modified to
P Success after 2 doses of event kð Þ≙
X2
j¼1
Sk tj‐1
  rk;j
n0j
ð11Þ
which is equivalent to (10), or to
P Success after 2 doses of event kð Þ¼CRCIk 2ð Þ≙
X2
j¼1
S tj‐1
  rk;j
n0j
ð12Þ
with Sk(tj−1) the probability of survival just to the k
th event,
and S(tj−1) the probability of survival to all K events; the
competing risk cumulative incidence rate CRCIk(2) from
(12) is a sub-distribution function and is known as the
“crude (cumulative) incidence function”, “k-specific risk”
or “k-specific probability of failure” [20, 21]. Note that we
keep on including the actuarial assumptions in (10) to
(12) from the Life-Table approach, but as far as we
know, all packages implementing the CRCIk(j) rates
use the KM approach assuming that the exact timing
of events is known.
The probability of the kth event in the jth interval counts
only occurrences of the kth event both in (11) and (12);
but in (11) survival considers all other competing events
as censored (that is, the subject has to survive only to the
kth event) while in (12) survival includes all competing
events. The standard KM and LT approaches use (11),
which overestimates (12). In fact, it can be proved in gen-
eral that CRCIk 2ð Þ≤
X2
j¼1Sk tj−1
   rk;j
n′j
≤ 1−S 2ð Þð Þ and
XK
k¼1CRCIk 2ð Þ ¼ 1−S 2ð Þð Þ , with S(2) the probability of
having no abortion at all after taking two misoprostol
doses [19, 21].
The rationale of (12) is obviously that to have a par-
ticular type of abortion (medical) during the jth interval,
patients need to survive up to the beginning of this
interval to both medical and surgical abortion (not only
to medical); see, e.g., [19] and [21].
There are several options for the standard error of
(12) [21]; the one usually recommended and imple-
mented in the Stata command stcompet [19] and in the
cmprsk R package [22] is
se CRCIk 2ð Þð Þ ≙
(
CRCIk 2ð Þ−CRCIk 1ð Þ½ 2 r1n1 n1 ‐r1ð Þ
þ n1‐rk;1
n1
 rk;1
n2
1
þ S 1ð Þ½ 2 n2‐rk;2
n2
 rk;2
n22
−2 CRCIk 2ð Þ‐CRCIk 1ð Þ½  rk;1n21
8<
:
9=
;
)
1
2
	
ð13Þ
with ∑k = 1
K rk,j = rj; an appropriate function of (13) for
computing the confidence interval is given in [19].
It should be noted that in the case of just one dose of
misoprostol (max j = 1), the CRCI estimate (12) becomes
the binomial proportion in (1), with the corresponding
standard errors being also equal, (13) and (4) respectively.
It should also be noted that independent of the number of
doses, the same happens when non-informative censored
data are absent (c1 = c2 = 0).
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In Table 1 we compare the point estimates and their
standard errors when using the binomial (bin), the
Kaplan-Meier (KM), the Life Table (LT), and the compet-
ing risk (CRCI) approaches, under 18 scenarios for the
rates of the main event (medical abortion), the competing
event (surgical abortion), and censored data (all other dis-
continued/loss-to-follow-up cases); in all scenarios the
censored data after the second dose have been mostly
(re)converted into the competing event “surgical abortion”
as per the usual design of these studies (see details of
Table 1 in Methods). For the survival approaches (KM, LT,
and CRCI) all events were assumed to occur exactly at
times (doses) 1 or 2; if we had instead used other (more
realistic) timings the results would be slightly different,
but the trends observed would remain the same.
It can be seen that the binomial proportion (bin) un-
derestimates the success rate after two doses of miso-
prostol, mainly when using the LTapproach which
includes the actuarial assumptions (columns {9}–{11});
the KM and LT approaches are appropriate if we want
to extrapolate to a population/situation where the com-
peting event (surgical abortion) does not exist. The
underestimation of bin with respect to CRCI is much
smaller (columns {9} and {12}), the CRCI rates being
appropriate when we want/expect medical and surgical
abortion to coexist in our population.
From Table 1 we see that the higher the censoring rate
the higher the under-estimation by the bin approach. We
also see that the lower the rate of the main event with the
second dose with respect to that of the first dose, the
smaller the under-estimation of the bin approach; in these
cases the combined rate would be mostly dominated by
the rate with only the first dose, meaning that the second
dose would be close to irrelevant and the binomial ap-
proach would then be close to being adequate. Finally we
see that the higher the success rate with the first dose, the
smaller the underestimation of the combined rate using
the bin approach with respect to the combined rate esti-
mations from the survival approaches.
The comparison of standard errors (columns {14}–{18}
on Table 1) shows that the bin approach has consistently
larger standard errors than the survival approaches; that
is, it underestimates the precision of the success rate es-
timation after two doses, particularly in comparison to
the LT approach (columns {14} and {16}). As when com-
paring point estimations, the smaller the success rate
with the second dose (in comparison to the rate with the
first dose) the smaller the underestimation of precision of
the bin approach with respect to the survival approaches;
also, in general the higher the rates of competing events
and censoring, the higher the underestimation of precision
of the bin approach with respect to the survival ap-
proaches. In contrast to the comparison of point estima-
tions, the higher the rate of the main event with the first
dose, the higher the underestimation of precision of the
bin approach compared to the survival approaches. Al-
though the precision of the bin approach increases with
higher rates of the main event with the first dose, we see
that the corresponding precisions for the survival ap-
proaches increase faster.
In terms of point estimations’ biases (underestimation)
of the bin approach the worst scenario is the sixth, cor-
responding to a low (70 %) rate of the main event with
the first dose, a high (66 %) rate of the main event with
the second dose, and high rates (20 % with the first
dose) of competing events and censoring. In terms of
precision biases (underestimation) of the bin approach
the worst scenario is the 18th, corresponding to a high
(90 %) rate of main event with the first dose, a high
(85 %) rate of the main event with the second dose, and
high rates (20 % with the first dose) of competing events
and censoring.
Discussion
The binomial proportion approach is still considered the
gold standard for assessing medical abortion success
when using multiple doses of misoprostol; we estimate
from the literature reviewed that in at least 80 % of the
relevant studies the binomial proportion approach is be-
ing used. We think the main reason is its seductive sim-
plicity. Many researchers are probably unaware of its
limitations, and the main purpose of this study is to
make these explicit.
The survival analysis approach, in any of the three
versions considered here, is adequate because it ac-
counts for non-informative censoring in general and,
eventually also for competing risk events (informative
censoring). The superiority of the survival approach
does not depend on the length of the periods between
doses (days or hours), but mainly on the number of
censored observations between consecutive doses; the
larger the number of censored observations the larger
the bias introduced by the binomial approach.
Medical abortion studies using misoprostol do not
usually have censored observations owing to loss to
follow-up (including “end of study”), because they are
designed so that all patients achieve success (complete
abortion) one way or the other, before the end of the
study. However, a non-negligible number of patients
might have their observations censored because of ex-
periencing the competing risk event “surgical abortion”,
which is not accounted for by the binomial approach.
WHO guidelines indicate that following administration
of misoprostol (using the combined regimen or mifepris-
tone and misoprostol for women with pregnancies of
gestational age up to 9 weeks) up to 90 % of women will
expel the products of conception (page 45, [1]). If we as-
sume that for gestational ages above 9 weeks the success
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rate (with the first dose of misoprostol) is in general
below 90 %, then the scenarios in Table 1 are relevant
from a clinical point of view.
When the time period between consecutive doses has
not been measured precisely, we could still use the sur-
vival approach, in this case not in terms of time (days or
hours) but in terms of number of doses; this will keep
the advantage of the survival approaches of accounting
for censored observations.
Because a binomial proportion does not account for the
fact that different individuals are exposed to different time
periods to the event of interest, as an alternative we might
be tempted to use a Poisson rates’ approach to account for
this exposure heterogeneity. However, Poisson rates (usu-
ally) assume that the probability of the event is the same
across time, which is generally not the case in medical
abortion studies using multiple doses of misoprostol.
The “intermediate outcome” approach, using for ex-
ample “principal stratification” might initially seem an
attractive alternative way to tackle the problem, because
it could be argued that surgical abortion is a “truncation
by death” intermediate outcome for medical abortion
[23]. However, the concept of intermediate outcomes re-
quires the intermediate event to be in the causal path
between intervention and the outcome, which is not the
case of surgical abortion (between the “nurses” interven-
tion and the outcome “medical” abortion). Surgical abor-
tion precludes medical abortion, but it is not a “cause”
of medical abortion; it is not possible to treat surgical
abortion independent of medical abortion (in the sense
of one being the potential cause of the other), because
they are just two (alternative and competing) ways of
reaching the same outcome/goal.
Conclusions
From the analysis and results of this paper we conclude
and recommend that binomial proportions should al-
ways be replaced by survival rates when assessing/com-
paring success rates of medical abortion with multiple
doses of misoprostol. The main reason is that binomial
proportions do not account for censored data or for
competing risks, and as a consequence:
• Binomial proportions tend to underestimate the real
success rate. The smaller the medical abortion rate of
success (closer to 50 % from above) and the larger the
rate of the surgical abortion rate (closer to 50 % from
below), the larger the underestimation in comparison to
the survival approaches (Kaplan-Meier, Life Table, and
Cumulative Incidence); and
• Binomial proportions tend to overestimate the real
standard error. This means that when binomial propor-
tions are used there is a tendency to miss statistically sig-
nificant differences between rates of success because the
corresponding standard errors are being overestimated.
The larger the medical abortion rate of success (closer to
100 %) and the larger the rate of the competing surgical
abortion event (closer to 50 % from below), the larger the
overestimation of standard error.
If we were interested in estimating the success rate of
medical abortion after two or more doses under the as-
sumption (counter-factual) that surgical abortion does not
exist (or it has been eliminated), then the Kaplan-Meier
and Life Table approaches are suggested as appropriate
because they consider the competing event (surgical abor-
tion) as non-informative censoring [20].
On the other hand, if we want to estimate the success
rate of medical abortion in the presence of competing
risks, in this case surgical abortion, then the use of the
Competing Risk Cumulative Incidence (CRCI) survival ap-
proach is indicated [19, 20]; when using this approach it is
important to present the rates for each of the competing
events (in this case “medical” and “surgical” abortion), as
the interpretation of the rate of the main event may de-
pend on the rate(s) of the other competing event(s) [20].
In some cases the broad conclusions might remain the
same independent of the approach used, but there is no
advantage in choosing an option that is consistently
biased with respect to more appropriate methods which
are now widely available in standard statistical packages.
Our recommendations can be extended to other sex-
ual and reproductive health studies where success is
assessed after multiple rounds/administrations of the
(experimental) treatment. For example, in assisted re-
productive technology (ART) for fertility treatment suc-
cess has traditionally been reported on a per-cycle basis
using binomial proportions; survival techniques are in-
creasingly used to estimate the cumulative rate of
achieving an ongoing pregnancy (or live pregnancy)
after successive cycles of in vitro fertilization or other
ART techniques and some adjustments for informative
censoring have been included [24, 25], but more formal
competing risks approaches could also be applied.
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